KAKouichi Asano

Kouichi Asano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kouichi Asano has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Takayuki Matsumoto

    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Morioka, Japan

    2 shared publications
  • Atsushi Hirano

    Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan

    1 shared publication
  • Junji Umeno

    Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan

    1 shared publication
  • Kenichi Sakurai

    1 shared publication
  • Mitsuo Iida

    1 shared publication
  • Motohiro Esaki

    Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan

    1 shared publication

Latest Publications

  • Contribution of susceptibility variants at FCGR2A and 13q12 to the risk of relapse among Japanese patients with ulcerative colitis

    by Kouichi Asano, Motohiro Esaki, Junji Umeno, Atsushi Hirano, Yuji Maehata, Tomohiko Moriyama, Shotaro Nakamura, Takayuki Matsumoto, Takanari Kitazono

    Recent genome-wide association studies have identified nearly 100 susceptibility genes for ulcerative colitis (UC). However, the contribution of susceptibility variants for UC to clinical outcome has scarcely been reported. The aim of this study was to investigate whether UC-associated genetic variants confer a risk of clinical relapse. One hundred and nine consecutive Japanese subjects with quiescent UC were recruited. Four genetic variants of HLA-DRB1*1502, rs6671847 at FCGR2A, rs17085007 at 13q12, and rs2108225 at SLC26A3 were genotyped by Invader assay. The clinical courses were followed after blood sampling, and the risk of relapse according to these genotypes was calculated by Cox proportional hazard model. During the mean follow-up period of 35 months (range 1–81 months), 49 of 109 subjects (45 %) relapsed. Carriers of the G allele of rs6671847 showed an increased risk of relapse compared with non-carriers [adjusted hazard ratio (HR), 2.27; 95 % confidence interval (CI), 1.20–4.32; p = 0.01]. Patients with the CT or TT genotypes of rs17085007 also had an increased risk of relapse compared to subjects with the CC genotype (for CT: adjusted HR, 2.16; 95 % CI, 1.10–4.23; p = 0.03; for TT: adjusted HR, 3.25; 95 % CI, 1.18–8.95; p = 0.02). These two risk variants multiplied the risk of relapse by 2.74 times (95 % CI, 1.10–4.23; p = 0.01) in patients with one risk genotype and 5.40 times (95 % CI, 2.06–14.13; p = 0.0006) in patients with both risk genotypes. Genetic variants of rs6671847 at FCGR2A and rs17085007 at 13q12 conferred a risk of relapse in patients with UC.


  • A novel bacterium Achromobacter xylosoxidans as a cause of liver abscess: Three case reports

    by Kouichi Asano, Shuji Tada, Takayuki Matsumoto, Shuichi Miyase, Takihiro Kamio, Kenichi Sakurai, Mitsuo Iida